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Abstract
Drug users are increasingly recognized as a key population driving human immunodeficiency virus (HIV) spread
in sub-Saharan Africa. To determine HIV-1 subtypes circulating in this population group and explore possible
geographic differences, we analyzed HIV-1 sequences among drug users from Nairobi, Mombasa, and Kisumu in
Kenya.We sequenced gag and env from 55 drug users. Subtype analysis from 220 gag clonal sequences from 54 of
55 participants (median= 4/participant) showed that 44.4%were A, 16.7%were C, 3.7%were D, and 35.2%were
intersubtype recombinants. Of 156 env clonal sequences from 48 of 55 subjects (median= 3/participant), 45.8%
were subtype A, 14.6%were C, 6.3%were D, and 33.3%were recombinants. Comparative analysis of both genes
showed that 30 (63.8%) participants had concordant subtypes, while 17 (36.2%) were discordant. We identified
one genetically linked transmission pair and two cases of dual infection. These data are indicative of extensive
HIV-1 intersubtype recombination in Kenya and suggest decline in subtype D prevalence.
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Introduction
It is estimated that *60 million people have been in-fected with the human immunodeficiency virus type 1
(HIV-1) and 25 million people have died of HIV-1-related
causes since the beginning of the epidemic. A hallmark of the
HIV-1 pandemic is the genetic diversity of viruses globally.
HIV-1 sequences cluster into distinct subtypes or clades, and
studies have shown that subtypes are unevenly distributed
around the world, but the underlying reasons for the distinct
geographical distribution have not been fully resolved.1,2
Sub-Saharan Africa bears the brunt of the epidemic, with
*70% of all infections, and the extensive HIV-1 subtype
diversity within the continent may pose an impediment to
vaccine development and antiretroviral drug efficacy.1,3,4
Furthermore, there is evidence that disease progression rate
and HIV-1 epidemic spread may differ within a geographic
area according to subtypes,5,6 and monitoring changing
subtype dynamics in a population may therefore be important
for clinical interventions among those infected and for
population-level strategies to curtail spread of the epidemic.
In many countries around the world, the HIV/AIDS epi-
demic is centered among particular high-risk groups, partic-
ularly young women, sex workers, men who have sex with
men, and injecting drug users (IDUs). Kenya is among
the countries of sub-Saharan Africa severely affected by
HIV/AIDS and in particular, studies have shown that HIV
prevalence among IDUs, at 52% and 15% in Nairobi and
Mombasa, respectively, is much higher than in the general
population.7 If countries such as Kenya are to make further
progress in reducing HIV-1 incidence, it is imperative that
efforts be devoted to key drivers of the epidemic such as
IDUs. Genetic studies of viruses circulating in key popula-
tions may offer insights into the effectiveness of public health
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interventions and provide information on pathogenesis and
design of novel strategies to treat and prevent HIV-1 trans-
mission. The main objective of this study was to determine
the HIV-1 subtype diversity among a key population group of
drug users in Kenya. We generated 376 full-length HIV-1
gag and env clonal sequences from 55 drug users, identified
from the three largest Kenyan cities of Kisumu, Nairobi, and
Mombasa. Our data reveal a complex picture of HIV-1 di-
versity in this population, suggestive of an active, ongoing
epidemic with multiple infections and recombination.
Between January 2011 and July 2012, drug users from
Kisumu, Mombasa, and Nairobi, the three largest cities in
Kenya, were recruited into a larger cross-sectional study in-
vestigating the social networks, status, and molecular epi-
demiology of HIV, hepatitis B virus (HBV), and hepatitis C
virus (HCV) among drug users in Kenya. Snowball sampling
was used to recruit a total of 673 drug users, both IDUs and
noninjecting drugs users (NIDUs). Study participants were
males or females, 18 years or older, who reported recreational
drug use, and had engaged in sexual activity at least once
monthly over the past 3 months before recruitment and
willing to provide blood samples for HIV testing. Participants
who met eligibility criteria were administered a study ques-
tionnaire that captured demographic information and history
of drug abuse, sexual behavior, employment status, health-
care access, sexual identity, and other risk factors for HIV
infection. Participants also received HIV prevention coun-
seling. Written informed consent was obtained from partici-
pants. The study protocol was approved by the Biomedical
Research Ethics Committee of the University of KwaZulu-
Natal, Kenyatta National Hospital/University of Nairobi
Ethics and Research Committee (KNH/UoN-ERC), and the
Health Research Ethics Board of the University of Manitoba.
Those who consented and agreed to provide blood were
sampled at identified sample collection centers. Both plasma
and serum specimens were aliquoted into two and stored
frozen at -80C until sent to laboratories for testing for
sexually transmitted infections (STIs), HIV, HBV, and HCV.
HIV infection status was determined using the fourth gen-
eration enzyme-linked immunosorbent assay (ELISA) kit
Vironostika HIV Uni-Form II Ag-Ab (Biomerieux) according
to the manufacturer’s instructions.
The QIAamp Viral RNA Mini Kit (Qiagen, Hilden,
Germany) was used to isolate viral RNA from plasma sam-
ples. For the gag polymerase chain reaction (PCR), RNAwas
used to synthesize complementary DNA (cDNA) using the
Thermoscript reverse transcription kit (Invitrogen, Life
Technologies, Foster City, CA) and the specific primer, GagD
reverse (5¢-AAT TCC TCC TAT CAT TTT TGG-3¢). The
Expand High Fidelity PCR System (Roche) was used to am-
plify the*1.6 kb gag gene using a nested PCR reaction. The
first-round PCR primers were GagD forward (5¢-TCT CTA
GCA GTG GCG CCC G-3¢) and GagD reverse. The second-
round PCR primers were GagA forward (5¢-CTC TCG ACG
CAG GAC TCG GCT T-3¢) and GagC reverse (5¢-TCT TCT
AATACTGTATCATCTGC-3¢). The resulting PCR product
was then purified using the Illustra GFX PCR DNA Gel
Band Purification Kit (GE Healthcare, Pittsburgh, PA) and
cloned into the PCR 2.1-TOPO vector (Invitrogen). Following
transformation, plasmid DNA (GeneJet Plasmid Mini Prep
Kit; Thermo Fisher Scientific) was isolated from white colo-
nies on plates containingXgal and screened for the presence of
the insert by digestion with theEcoRI restriction enzyme (New
England BioLabs, Ipswich, MA).
For the env PCR, cDNA was synthesized using the
SuperScript III protocol according to the manufacturer’s
instructions (Invitrogen) with the specific primer, OFM19
(5¢-GCACTCAAGGCAAGCTTTATTGAGGCTTA-3¢). The
first-round PCR was carried out using the High Fidelity
Platinum enzyme (Invitrogen) and the external primers used
were VIF1 (5¢-GGGTTTATTACAGGGACAGCAGAG-3¢)
and OFM19 5¢-GCACTCAAGGCAAGCTTTATTGAGGC
TTA-3¢). Phusion High Fidelity polymerase was used for the
second-round PCR with the primers ENV A (5¢-GCTTAG
GCATCTCCTATGGCAGGAAGAA-3¢) and ENV N (5¢-
CTGCCAATCAGGGAAGTAGCCTTGTGT-3¢).8 The final
PCR product (*3.2 kb) was ligated into the pcDNA3.1.V5-
His TOPO TA vector according to the manufacturer’s
instructions (Invitrogen). Plasmid DNA was isolated from
individual randomly picked white bacterial colonies and di-
gested with the HindIII and NotI restriction enzymes (New
England BioLabs) to screen for the presence of the insert.
For single genome amplification (SGA) of the full-length
gag gene, a limiting endpoint dilution was performed on
cDNA synthesized for one participant (PID 426) to confirm
the possibility of dual infection suggested by the bulk clonal
sequences. SGA was performed as previously described.9
Briefly, cDNA was serially diluted in replicates of eight PCR
wells and gag PCRwas performed as described above. cDNA
dilutions were tested to identify a dilution where *30% of
wells were positive for amplification products. All products
derived from this dilution were sequenced directly.
Gag and env sequencing were performed using the ABI
PRISM Big Dye Terminator Cycle Sequencing Ready Re-
action kit version 3.4 (Applied Biosystems, Foster City, CA).
Sequences were assembled and edited using Sequencher
Program v8.1.2 (Gene Codes Corporation) and aligned using
Table 1. Characteristics of Study Participants




Median age (IQR) 30 (26–34)















HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human
immunodeficiency virus; IDU, injecting drug use; IQR, interquartile
range; NIDU, noninjecting drug use.
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ClustalW. Maximum likelihood phylogenetic trees were
constructed as implemented by Geneious v.8.1.6 to evaluate
clustering of sequences with each other as well as with sub-
type reference strains obtained from the Los Alamos HIV
sequence database (www.hiv.lanl.gov/content/sequence/
NEWALIGN/align.html). The maximum likelihood tree to-
pology was inferred in phyML with a general time-reversible
(GTR) substitution model (gamma distribution). Branching
topology was visualized in FigTree (http://tree.bio.ed.ac.uk/
software/figtree). Intralaboratory plasmid contamination was
assessed using different methods: first, by using neighbor-
joining phylogenetic trees to confirm phylogenetic clustering
within and between participants. Second, sequences were
blasted against sequences present in GenBank using the
BLAST tool (GenBank, National Centre for Biotechnology
Information). Finally, ViroBlast was used to compare all
sequences to HIV sequences derived in our laboratory (http://
indra.mullins.microbiol.washington.edu/viroblast/viroblast.
php). Any clones that were nearly identical against local and
published databases were removed from analysis.
The REGA HIV-1 subtyping Tool Version 2.0 (http://
bioafrica.net/regagenotype/html/subtypinghiv.html) and the
Recombinant Identification Program, RIP version 3 (www
.hiv.lanl.gov/content/sequence/RIP/RIP.html) were used to
infer subtypes. Subtype breakpoints were confirmed using
Simplot v3.5. Using the predicted recombination breakpoints,
FIG. 1. Relative proportions of pure subtypes and intersubtype recombinants among drug users in Kenya. (A) Proportion
of participants infected with pure and recombinant subtypes together with the breakdown of the relative recombinant
percentages based on HIV-1 gag sequences. (B) Proportion of participants infected with pure and recombinant subtypes
together with the breakdown of the relative recombinant percentages based on HIV-1 env sequences and (C) relative
proportions of participants containing pure subtypes, recombinants, or a mixture of both pure and recombinant subtypes for
either the gag or env region of the HIV-1 genome. HIV-1, human immunodeficiency virus type 1.
502 GOUNDER ET AL.
FIG. 2. Distribution (%) of HIV-
1 subtypes and intersubtype re-
combinants among drug users in
Nairobi, Kisumu, and Mombasa
based on the number of gag and
env clonal sequences obtained for
each region. The number of par-
ticipants screened for each city in
Kenya is shown within the indi-
vidual subtype bars.
FIG. 3. Schematic representation of concordant and discordant subtypes based on full-length clonal gag and env genes
analyzed from drug users in Kenya. (A) gag and env gene structure of the 30 concordant subtypes. (B) Gene structures of
full-length gag and env showing discordant subtype distribution in 17 drug user participants. Clonal sequencing revealed
mixed subtypes (PID 426 had mixed subtypes in the gag region, while PID 575 had mixed subtypes in the env region).
*Represents known injecting drug users. Subtype classification of each gene is indicated. Subtype distribution is shown in
different colors (A, red; C, yellow; D, light blue; G, dark green, and H, light green). Note that the gene lengths are not drawn
to scale.
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sequence fragments were trimmed, realigned to subtype ref-
erence sequences, and phylogenetic trees were constructed to
verify subtype classification for each sequence fragment be-
tween identified subtype breakpoints.
Of the 673 study participants enrolled into the parent drug
user study, 80 (11.9%) were HIV infected. Out of 80 samples
subjected to amplification protocols, only 55 (69%) yielded
an amplicon. The demographic and epidemiological char-
acteristics of these participants are shown in Table 1. The
majority of participants were male (43 of 55, 78.2%) and the
median age of the participants was 30, with an interquartile
range (IQR) of 26–34. Drug users were recruited from three
sites within Kenya, 10 participants (18.2%) from Nairobi, 17
(30.9%) from Kisumu, and 28 (50.9%) from Mombasa. Only
17 (30.9%) of the participants self-reported as IDUs. Six of
55 (10.9%) were positive for HBV and 15 of 55 (27.3%)
tested positive for HCV.
From the 55 HIV-positive drug users with HIV PCR
products that could be evaluated, we successfully generated a
total of 220 gag clonal sequences from 54 of the 55 partici-
pants (98.2%) and 156 env clonal sequences from 47 of 55
(85.5%) participants. The median number of sequences an-
alyzed for gag was four per participant and three sequences
for env. The remaining samples either had negative PCR
results or ambiguous sequences, which were discarded.
FIG. 4. Phylogenetic analysis of drug user participants
from three major cities in Kenya. (A) Maximum likelihood
trees were constructed using 220 HIV-1 full-length gag
clonal sequences collected from drug user participants re-
cruited from Nairobi (green circles), Kisumu (blue circles)
and Mombasa (red circles). Possible linked participants
(PIDs 552 and 527) are highlighted in green text and pos-
sible dual infected participant is highlighted in red text (PID
426). (B) Detailed phylogenetic analysis of possible dual in-
fected drug user participant 426 (red) and epidemiologically-
linked drug users (green) are shown. Both clonal sequences
(solid red circles) together with single genome amplification
(SGA) derived gag sequences (open red circles) for PID 426
show infection with subtypes A, D, AD and ADH. Phylo-
genetic analysis shows strong bootstrap support of epide-
miological linkage between participants PID 552 and 527
(green circles) after sequences were downloaded and in-
cluded in phylogenetic analysis after BLAST analysis of
individual participant sequences. (C) Phylogenetic analysis
of 156 HIV-1 full-length env sequences from drug user
participants from Nairobi (green), Kisumu (blue) and
Mombasa (red). Possible dual infected drug user participant
426 (red text) and epidemiologically-linked drug users
PID 552 and 527 (green text) are shown. (D) Detailed
phylogenetic analysis of the epidemiologically-linked par-
ticipants PID 552 and 527 (green) after adding downloaded
BLAST analysis sequences suggest strong linkage be-
tween the two participants. All HIV-1 reference sequences
representing genetic subtypes were obtained from the Los
Alamos National Laboratory HIV Sequence Database in-
cluded: Ref.A1.RW.92, Ref.A1.UG.92, Ref.A1.AU.03,
Ref.A2.CD.97, Ref.A2.CY.94, Ref.A2.CM.01, Ref.B.NL.00,
Ref.B.US.98, Ref.B.FR.83, Ref.C.ET.86, Ref.C.BR.92,
Ref.C.ZA.04, Ref.C.IN.95, Ref.D.CD.83, Ref.D.TZ.01,
Ref.D.UG.94, and Ref.D.CM.01 for both gag and env (blue
text). Bootstrap support ‡70 is indicated with an asterisk (*).
The gray boxes highlight alternate individual participant
sequence clusters.







Gag sequences indicated that 24 (44.4%) drug users were
infected with subtype A, 9 (16.7%) were infected with sub-
type C, 2 (3.7%) were infected with subtype D, and the re-
maining 19 (35.2%) were infected with intersubtype
recombinants (Fig. 1A). Similarly, env sequence analyses
revealed that 22 (45.8%) participants were infected with
subtype A, 7 (14.6%) were infected with subtype C, 3 (6.3%)
were infected with subtype D, and the remaining 16 (33.3%)
were infected with recombinants (Fig. 1B). We next deter-
mined the number of participants infected with a pure sub-
type, recombinant, or a mixture of viruses (sequences
containing both a pure subtype and a recombinant virus)
(Fig. 1C). Both gag and env sequence data showed that ma-
jority of individuals were infected with a pure subtype
(N = 35, 64.8% and N = 32, 66.7%, for gag and env, respec-
tively), compared to (N= 18) 33.3% and (N = 15) 31.3% of
individuals infected with recombinant viruses and a rela-
tively low number of individuals infected with a mix of both
pure and recombinant viruses [N = 1 (1.9%) and N = 1 (2%),
respectively].
Our data provide potentially important insights into the
changing HIV-1 subtype dynamics of the Kenyan epidemic,
particularly among the key population of drug users. Our data
are consistent with previous studies that subtype A is the
predominant subtype in Kenya; however, we found that in
this population group, subtype C (16.7% in gag and 14.6% in
env), was the second most common subtype, with a far less
contribution of subtype D (3.7% in gag and 6.3% in env) than
the anticipated *9% to 20% based on majority of previous
studies.3,10–12 Remarkably, despite higher percentage of pure
subtype C infections compared to D in both gag and env in
this cohort, AD were the majority intersubtype recombinants
consisting of 68.4% in gag and 50% in env (Fig. 1A, B),
suggesting that recombination may not be random and sub-
type D is more likely to generate recombinants compared to
subtype C. Alternatively, subtype D may have existed at
higher prevalence in the past and may be decreasing, with its
remnants still evident in the form of recombinants. Overall,
our data are consistent with predominance of HIV-1 subtype
A in Kenya, but relatively higher percentage of subtype C,
and lower percentage of subtype D than has been reported
previously.
We next assessed whether there are differences in subtype
distribution in the geographically spread out Kenyan towns of
Kisumu (Western Kenya), Mombasa (Coast region), and
Nairobi (Central Kenya) where there may be differences in
socio-demographic factors and risk behaviors influencing
HIV spread. HIV-1 subtype A was the predominant subtype
in all three Kenyan cities irrespective of the virus gene ana-
lyzed (Fig. 2). The percentage of participants whose se-
quences clustered with subtype A references in Nairobi
accounted for 50% in both gag and env, respectively, com-
pared to 56.3% and 62.5% in Kisumu. For the Mombasa
dataset, the percentages of individuals infected with subtypes
A was lower at 35.7% and 28.6% for gag and env, respec-
tively, just slightly higher than the percentages observed for
subtype C at 31.8% and 22.7% for gag and env, respectively.
In contrast, for all three cities, the percentage of partici-
pants infected with subtype D was generally below 10%. In
Nairobi, 10% of participants could be classified as subtype D,
but none of the env sequences were subtype D, while 10% of
participant env sequences were classified as subtype C with
no gag subtype C detected. Among sequences generated from
participants in Kisumu, the same percentage of participants
was infected with subtype D (6.3%) and C (6.3%) in both gag
and env, respectively. InMombasa, 9.1% of participants were
subtype D based on env sequences, with no gag subtype D
sequences detected. Of the intersubtype recombinants, only
subtype AD was found in significant percentages. In Nairobi
and Kisumu, 30% and 12.5% of participants were subtype
AD for both gag and env, respectively, compared to 28.6% in
gag and 13.6% in env in Mombasa. All other recombinants
were below 18% prevalence at all sites irrespective of gene
region analyzed.
It is therefore noteworthy that in this study, we observed a
trend whereby subtype C mostly surpassed or was almost
equal to subtype D in percentage of sequences analyzed, a
trend that was most prominent in Mombasa. Mombasa is a
coastal town located near the border and with strong cultural
links to Tanzania, Kenya’s southern neighbor, which itself
has a sizable HIV-1 subtype C epidemic. It is therefore
possible that high prevalence of C represents recent trans-
missions from movement of people across the Kenya–
Tanzania border. HIV-1 subtype A was generally highest in
prevalence, followed by AD intersubtype recombinants, de-
spite the lower prevalence of pure D compared to C se-
quences. Our data call for further studies to explore biological
differences that may explain the changing subtype landscape.
Although one study suggested that women infected with
HIV-1 subtype C viruses in Kenya had significantly higher
viral loads and lower CD4 cell counts compared to clade A or
D infection,10 other studies from Kenya have demonstrated
that subtype D infection is associated with a faster rate of
CD4+ T decline and time to AIDS compared to subtypes A or
C.11,13 It is plausible that faster progression to AIDS for
subtype Dmay result in reduced lifetime odds of transmitting
the virus, which in turn may result in reduced prevalence of
this subtype in a heterogeneous epidemic. Alternatively,
subtype D may have specific biological characteristics that
provide a disadvantage for its transmission efficiency, or the
vice-versa may be true for subtype C. In support of these
hypotheses are studies showing subtype-specific differences
in Pol-mediated replicative fitness14 and in Nef protein
functions, with subtype D suggested to be more virulent
compared to either subtype A or C.15
We next assessed subtype concordance within individuals
for the two genes analyzed. Of the 47 participants with both
gag and env sequences, 30 (63.8%) showed subtype con-
cordance of the gag and env sequences (17 subtype A, 6
subtype C, 1 subtype D, and 6 had AD intersubtype recom-
binants, with recombination breakpoints more common at the
3¢ end of gag and env, although the dataset was too small to
perform statistical associations) (Fig. 3A). Seventeen par-
ticipants (36.2%) had discordance in subtype between gag
and env with a variety of different subtype combinations and
recombinant breakpoints (Fig. 3B) (the remaining 8 of 55
participants could not be included in this analysis because
they had a negative PCR for env). Among the discordant
participants, the subtype combinations included two each of
A/AC, C/AC, and AD/D and one each of A/AD, AD/A, CD/C,
D/ACD, ADG/CD, AC/AD, AD/CD, ADGH/A, and ACGH/C
between the gag and env genes, respectively. Two participants
(PID 426 and 575) showed evidence of dual infection. PID 426
had a combination of AD and ADH gag sequences with
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corresponding pure subtype A env clonal sequences. Partici-
pant 575 had a recombinant AD gag sequence with a mixture
of AD and pure A env sequences. In this cross-sectional study,
it was not possible to determine whether these sequences
represent mixed infections or infection with pure subtype
viruses that then undergo recombination in the infected patient.
However, the presence of discordant subtypes in gag versus
env suggests either multivariant transmitted/founder viruses or
dual infections with subsequent generation of viral recombi-
nants among drug user populations in Kenya.
To determine whether the discordant mixed infections
were representative of dual infection, we subjected the gene
sequences to further phylogenetic analysis. We defined dual/
mixed infection as an infection with two phylogenetically
distinct viruses. Viruses from one drug user (PID 426) from
Mombasa grouped separately on the gag phylogenetic tree
demonstrating that this individual was infected with two
different viruses (Fig. 4A). Gag viral populations grouped as
subtype AD (n= 2 sequences), with a second branch of re-
combinant subtype ADH (n = 7) sequences. To confirm these
cases of dual infection in gag, we performed SGA to ame-
liorate potential bias from PCR-generated recombination or
resampling (Fig. 4B). The resulting SGA sequences con-
firmed the phylogenetically distinct sequences present in
participant 426 (shown in orange), including pure subtype
A and D sequences that were not picked up by clonal se-
quencing. However, phylogenetic analysis did not reveal any
possible dual infection within the env region, with all se-
quences forming a single cluster (Fig. 4C). In addition,
among these drug users appeared a case of epidemiologically
linked viruses in participants PID 552 and PID 527, with
sequences that clustered together for both gag and env with
high bootstrap upon stringent phylogenetic analysis, with
closely related sequences downloaded after a BLAST search
as shown in Figure 4A–D. Both participants are females from
Mombasa who may have shared a sexual partner or were part
of the same drug user social network.
Our study has some limitations worth highlighting. First,
we lacked clinical history and immune profile data such as
CD4 counts and viral load, which would have been useful for
more detailed interpretation of data from the study. In addi-
tion, this was a small sample size, cross-sectional drug user
cohort study, restricted only to major urban sites in Kenya
and may therefore not be representative of other key popu-
lation groups that drive the epidemic in the region. Moreover,
of 80 HIV-positive samples, we could amplify the virus from
only 55 (68.8%), indicating either poor quality or extreme
genetic diversity in the remaining samples, and our data
should therefore be interpreted with caution. Last, as under-
lined by our analysis of gag and env regions, recombination
patterns in a heterogeneous epidemic are complex and will
require generation of full-length single genome level data to
fully understand the changing dynamics of viral genotypes
and infer the possible implications for medical and public
health interventions.
In conclusion, our study highlights the high prevalence of
HIV-1 subtype A in a key population group within the ep-
idemic in Kenya. Our data suggest that HIV-1 subtype C is
an important component of the epidemic within this group,
with a hint of geographical differences across the Kenya.
Interestingly, we found lower prevalence of subtype D than
has been reported in most previous studies, and despite
this low prevalence, subtype D comprised the majority of
intersubtype recombinants. Further studies focusing on
longitudinal studies and full-length genotypic character-
ization of viral variants in larger key population groups in
Kenya are recommended to optimize public health strate-
gies for interventions.
Sequence Data
Full-length gag and env nucleotide sequences obtained in
this study have been submitted to the GenBank database
under accession numbers: KU921705-KU922091.
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